Shanghai Medicilon Inc.

Informe acción SHSE:688202

Capitalización de mercado: CN¥4.7b

Shanghai Medicilon Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Shanghai Medicilon's earnings have been declining at an average annual rate of -15.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 20.2% per year.

Información clave

-15.2%

Tasa de crecimiento de los beneficios

-15.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences 26.8%
Tasa de crecimiento de los ingresos20.2%
Rentabilidad financiera-11.8%
Margen neto-28.1%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Shanghai Medicilon Inc. (SHSE:688202) Might Not Be As Mispriced As It Looks

Sep 27
Shanghai Medicilon Inc. (SHSE:688202) Might Not Be As Mispriced As It Looks

Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?

Jun 07
Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?

Market Cool On Shanghai Medicilon Inc.'s (SHSE:688202) Revenues Pushing Shares 27% Lower

Apr 25
Market Cool On Shanghai Medicilon Inc.'s (SHSE:688202) Revenues Pushing Shares 27% Lower

Desglose de ingresos y gastos

Cómo gana y gasta dinero Shanghai Medicilon. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SHSE:688202 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 24984-27723598
30 Jun 241,015-270253109
31 Mar 241,174-172262119
31 Dec 231,366-33264122
30 Sep 231,602175226132
30 Jun 231,788342228133
31 Mar 231,754363239128
31 Dec 221,659338228123
30 Sep 221,621379220109
30 Jun 221,42533218996
31 Mar 221,30931415386
31 Dec 211,16728214178
30 Sep 211,01923612971
30 Jun 2189119611859
31 Mar 2177515910452
31 Dec 206661299245
30 Sep 20569958139
30 Jun 20511867535
31 Mar 20467707431
31 Dec 19449677027
30 Sep 19407646123
31 Dec 18325614616
31 Dec 17249423610
31 Dec 1623243289
31 Dec 1516426390
31 Dec 14109-3340

Ingresos de calidad: 688202 is currently unprofitable.

Margen de beneficios creciente: 688202 is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 688202 is unprofitable, and losses have increased over the past 5 years at a rate of 15.2% per year.

Acelerando crecimiento: Unable to compare 688202's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 688202 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-14.4%).


Rentabilidad financiera

Alta ROE: 688202 has a negative Return on Equity (-11.77%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado